Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

25 May 2023 07:00

RNS Number : 5737A
Sabre Insurance Group PLC
25 May 2023
Ā 

25 May 2023

Ā 

Sabre Insurance Group plc

Trading Update

Full year guidance reiterated

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading motor insurance underwriters, today provides an update on trading for the period from 1 January 2023 to 30 April 2023 ahead of its Annual General Meeting ("AGM") later this morning.

Unaudited

Unaudited

4 months ended

4 months ended

Ā 

Ā 30 Apr 2023

30 Apr 2022

Gross written premium - Motor

Ā£47.9m

Ā£45.3m

Gross written premium - Motorcycle

Ā£6.3m

Ā£12.0m

Gross written premium - Taxi

Ā£4.7m

Ā£2.5m(1)

Gross written premium - Total

Ā£58.9m

Ā£59.8m

(1) = Disclosed as part of 'Motor' in the May 2022 trading update

Business highlights for the first four months of 2023

‒ Gross written premium in Motor has increased year on year, with profitability in line with expectations and ahead of the same period last year

‒ Further progress in improving the profitability of the Motorcycle business with the current run-rate performance in-line with expectations and anticipated to deliver a positive contribution to profit in 2023

‒ Underwriting actions to improve the profitability of the Taxi business are anticipated to continue through 2023, reflected in current reduced premium run-rate of this business

‒ Ongoing focus on profitability, not volume, with total policy count of 275k as at 30 April 2023 (31 December 2022: 304k) including 54k motorcycle policies (31 December 2022: 74k) and 14k taxi policies (31 December 2022: 12k)

‒ Whilst core Motor policy count declined early in the year, we have seen a return to growth in policy count in recent weeks

‒ Post-dividend solvency capital ratio at 31 March 2023 of 172% (31 March 2022: 160%)

Market trends

‒ Claims inflation for 2023 anticipated to remain at c.10%, as previously guided

‒ Evidence of positive momentum in market pricing since late March, with this trend anticipated to continue in the coming months

Full year guidance reiterated

‒ High single-digit growth in overall gross written premium anticipated for the full year

‒ Low double-digit growth in core Motor business gross written premium somewhat offset by a reduction in the Motorcycle and Taxi businesses as underwriting actions take hold

‒ Combined operating ratio expected to be between 85% to 90%

‒ Expected expense ratio strain in H1, and improvements on loss ratios throughout 2023 as pricing actions earn through, means H1 combined operating ratio likely to be higher than the expected 2023 full year position

‒ Note that this guidance is carried forward from year-end on an IFRS4-equivalent basis

Geoff Carter, Chief Executive Officer of Sabre, commented:

"I am pleased to be able to continue my message of cautious optimism from our full-year results into our first update for 2023, and indeed I am feeling slightly more optimistic given strong volumes in recent weeks.

In particular, we have been encouraged by the trends that we have been seeing from mid-March and into May. There is clear evidence that market pricing is improving, and we have seen weekly gross written premiums across this period in our core Motor business over 20% higher than the same time last year. We anticipate this trend of improving market pricing will continue, albeit it is too early to tell what the pace and trajectory of improvement will be, and are confident in our ability to continue to grow volumes at the appropriate margin. We are currently in the fortunate position of making pricing decisions designed to find an optimal point between volume growth and margin enhancement.

We expect the loss ratios in the core Motor business to improve through the rest of 2023, with pricing actions reflecting ongoing inflation. Volumes for the Taxi business have been suppressed while this market segment remains challenging. The actions we took last year and this year to increase the profitability of the Motorcycle businesses should generate a positive contribution to profit.

If these positive market pricing trends and run-rates continue through the rest of the year, we anticipate a strong bounce-back in earnings compared to 2022."

Ā 

Investor enquiries

01306 747 272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Teneo

sabre@teneo.com

James Macey White / Eleanor Pomeroy

Ā 

LEI Code: 2138006RXRQ8P8VKGV98

Ā 

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
TSTSEMFALEDSEFI
Date   Source Headline
2nd Jun 20267:00 amRNSOn-market Share Buyback Programme of £5m
27th May 20269:36 amRNSDirector Declaration
21st May 202611:20 amRNSResult of AGM
21st May 20267:00 amRNSTrading Update
12th May 20261:22 pmRNSDirector/PDMR Shareholding
22nd Apr 20261:18 pmRNSDirector/PDMR Shareholding
14th Apr 20263:48 pmRNSDirector/PDMR Shareholding
13th Apr 20263:18 pmRNSDirector/PDMR Shareholding
8th Apr 20262:56 pmRNSDirector/PDMR Shareholding
8th Apr 202610:41 amRNSDirector/PDMR Shareholding
8th Apr 202610:39 amRNSDirector/PDMR Shareholding
30th Mar 202611:01 amRNSNotice of AGM
11th Mar 20261:49 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSFull-year results 2025
11th Feb 20261:27 pmRNSDirector/PDMR Shareholding
13th Jan 20263:43 pmRNSDirector/PDMR Shareholding
11th Dec 20251:29 pmRNSDirector/PDMR Shareholding
11th Nov 20251:40 pmRNSDirector/PDMR Shareholding
31st Oct 20258:00 amRNSTotal Voting Rights
23rd Oct 20259:58 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSTrading Update
14th Oct 20257:49 amRNSHolding(s) in Company
13th Oct 20253:56 pmRNSDirector/PDMR Shareholding
3rd Oct 20257:00 amRNSCompletion of Buyback Programme
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 202510:21 amRNSTotal Voting Rights
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20251:01 pmRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20254:52 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 202512:24 pmRNSDirector/PDMR Shareholding
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.